Food and Drug Administration (FDA) for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) and at least one weight-related condition, such as type 2 diabetes, high blood pressure, or high cholesterol
Clinical trials have validated the effectiveness of semaglutide in managing weight , displaying substantial body weight reductions compared to placebos or alternative weight loss strategies
Waar semaglutide vooral op GLP-1 werkt, wordt Retatrutide onderzocht vanwege de gecombineerde werking op GLP-1-, GIP- en glucagonreceptoren
Do not use other GLP-1 RAs
Men gr det att kpa saker med till exempel bitcoin
Dosing is personalised based on treatment goals, HbA1c levels, body weight, renal function, concurrent medications, and tolerability